Colorectal Cancer: Update Bulletin #3 [June 2018]

Topics covered include expert opinions on; the potential of Treos Bio’s PolyPEPI 1018, an investigational precision vaccine for patients with metastatic colorectal cancer; views on new data announced by Genentech (Roche) from the Phase III IMblaze370 study evaluating the MEKi/anti-PD-L1 combination of cobimetinib (Cotellic) and atezolizumab (Tecentriq) compared to regorafenib (Stivarga) in patients with microsatellite stable (MSS) mCRC; Innate Pharma’s announcement of preliminary data from an ongoing Phase I dose escalation and expansion study evaluating the combination of monalizumab, a first-in-class mAb targeting NK and T cell inhibitory checkpoint receptor NKG2A, with durvalumab (Imfinzi; AstraZeneca).

Business Questions:

• What are KOLs’ reactions to PolyPEPI 1018?
• Which patients do KOLs anticipate PolyPEPI 1018 will be suitable for? 
• What does the future development of PolyPEPI 1018 look like according to KOLs?
• To what extent are KOLs surprised by these recent data from the IMblaze370 study and what are the reasons behind this result?
• What does the future hold for MEK inhibitor and immune-oncology combinations such as cobimetinib and atezolizumab?
• How do KOLs react to the data from the Phase I dose study of monalizumab and durvalumab? 
• Do KOLs have concerns about the safety profile of the monalizumab and durvalumab combination?
• What are the next steps for investigations into the combination of monalizumab and durvalumab? 
• Where and how do KOLs anticipate monalizumab and durvalumab in combination will be used in the future?